|
🐢
|
Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth
10 auth.
F. Bussolino,
M. F. Renzo,
M. Ziche,
E. Bocchietto,
M. Olivero,
L. Naldini,
...
G. Gaudino,
L. Tamagnone,
A. Coffer,
P. Comoglio
|
10 |
1992 |
10
🐢
|
|
🐢
|
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.
Selma Pennacchietti,
P. Michieli,
M. Galluzzo,
M. Mazzone,
S. Giordano,
P. Comoglio
|
10 |
2003 |
10
🐢
|
|
🐢
|
MET signalling: principles and functions in development, organ regeneration and cancer
L. Trusolino,
A. Bertotti,
P. Comoglio
|
10 |
2010 |
10
🐢
|
|
🐢
|
Plexins Are a Large Family of Receptors for Transmembrane, Secreted, and GPI-Anchored Semaphorins in Vertebrates
12 auth.
L. Tamagnone,
Stefania Artigiani,
Hang Chen,
Zhigang He,
G. Ming,
Hongjun Song,
...
A. Chédotal,
M. Winberg,
C. Goodman,
M. Poo,
M. Tessier-Lavigne,
P. Comoglio
|
10 |
1999 |
10
🐢
|
|
🐢
|
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family
9 auth.
C. Ponzetto,
A. Bardelli,
Z. Zhen,
F. Maina,
P. Zonca,
S. Giordano,
...
A. Graziani,
G. Panayotou,
P. Comoglio
|
9 |
1994 |
9
🐢
|
|
🐜
|
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
28 auth.
A. Bertotti,
Giorgia Migliardi,
F. Galimi,
F. Sassi,
Davide Torti,
C. Isella,
D. Corà,
F. Di Nicolantonio,
M. Buscarino,
Consalvo Petti,
D. Ribero,
N. Russolillo,
A. Muratore,
P. Massucco,
A. Pisacane,
...
L. Molinaro,
E. Valtorta,
A. Sartore-Bianchi,
M. Risio,
L. Capussotti,
M. Gambacorta,
S. Siena,
E. Medico,
A. Sapino,
S. Marsoni,
P. Comoglio,
A. Bardelli,
L. Trusolino
|
9 |
2011 |
9
🐜
|
|
🦁
|
Drug development of MET inhibitors: targeting oncogene addiction and expedience
P. Comoglio,
S. Giordano,
L. Trusolino
|
9 |
2008 |
9
🦁
|
|
🐜
|
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
30 auth.
A. Sartore-Bianchi,
L. Trusolino,
C. Martino,
K. Bencardino,
S. Lonardi,
F. Bergamo,
V. Zagonel,
F. Leone,
Ilaria Depetris,
E. Martinelli,
T. Troiani,
F. Ciardiello,
P. Racca,
A. Bertotti,
G. Siravegna,
...
V. Torri,
A. Amatu,
S. Ghezzi,
G. Marrapese,
L. Palmeri,
E. Valtorta,
A. Cassingena,
C. Lauricella,
A. Vanzulli,
D. Regge,
S. Veronese,
P. Comoglio,
A. Bardelli,
S. Marsoni,
S. Siena
|
9 |
2016 |
9
🐜
|
|
🐢
|
Scatter-factor and semaphorin receptors: cell signalling for invasive growth
L. Trusolino,
P. Comoglio
|
9 |
2002 |
9
🐢
|
|
🐢
|
Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET.
7 auth.
L. Naldini,
E. Vigna,
R. Narsimhan,
G. Gaudino,
R. Zarnegar,
G. Michalopoulos,
...
P. Comoglio
|
9 |
1991 |
9
🐢
|
|
🐢
|
Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.
12 auth.
L. Naldini,
K. Weidner,
E. Vigna,
G. Gaudino,
A. Bardelli,
C. Ponzetto,
...
R. Narsimhan,
'. GuidoHartmann,
R. Zarnegar,
G. Michalopoulos,
Walter Birchmeierl,
P. Comoglio
|
9 |
1991 |
9
🐢
|
|
🐜
|
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.
28 auth.
A. Bardelli,
S. Corso,
A. Bertotti,
S. Hobor,
E. Valtorta,
G. Siravegna,
A. Sartore-Bianchi,
E. Scala,
A. Cassingena,
D. Zecchin,
M. Apicella,
Giorgia Migliardi,
F. Galimi,
C. Lauricella,
C. Zanon,
...
T. Perera,
S. Veronese,
G. Corti,
A. Amatu,
M. Gambacorta,
L. Diaz,
M. Sausen,
V. Velculescu,
P. Comoglio,
L. Trusolino,
F. Di Nicolantonio,
S. Giordano,
S. Siena
|
9 |
2013 |
9
🐜
|
|
🐢
|
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor.
10 auth.
L. Naldini,
L. Tamagnone,
E. Vigna,
M. Sachs,
G. Hartmann,
W. Birchmeier,
...
Daikuhara Yasushi,
H. Tsubouchi,
F. Blasi,
P. Comoglio
|
9 |
1992 |
9
🐢
|
